<code id='FFA501220E'></code><style id='FFA501220E'></style>
    • <acronym id='FFA501220E'></acronym>
      <center id='FFA501220E'><center id='FFA501220E'><tfoot id='FFA501220E'></tfoot></center><abbr id='FFA501220E'><dir id='FFA501220E'><tfoot id='FFA501220E'></tfoot><noframes id='FFA501220E'>

    • <optgroup id='FFA501220E'><strike id='FFA501220E'><sup id='FFA501220E'></sup></strike><code id='FFA501220E'></code></optgroup>
        1. <b id='FFA501220E'><label id='FFA501220E'><select id='FFA501220E'><dt id='FFA501220E'><span id='FFA501220E'></span></dt></select></label></b><u id='FFA501220E'></u>
          <i id='FFA501220E'><strike id='FFA501220E'><tt id='FFA501220E'><pre id='FFA501220E'></pre></tt></strike></i>

          Home / comprehensive / focus

          focus


          focus

          author:hotspot    Page View:4823
          Alastair Grant/AP

          LONDON — AstraZeneca said Thursday it would purchase the French firm Amolyt Pharma in a deal worth up to $1 billion, picking up a rare disease drug in a pivotal trial.

          The acquisition includes an upfront payment of $800 million in cash, plus another $250 million if regulatory milestones are met. 

          advertisement

          AstraZeneca framed the deal for Amolyt, which has focused on treatments for rare endocrine diseases, as a boost for its own rare disease pipeline. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In